Generate Biomedicines, Inc. (GENB)
| Market Cap | n/a |
| Revenue (ttm) | 31.89M +55.9% |
| Net Income | -203.15M |
| EPS | n/a |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About GENB
Generate Biomedicines is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Our vision is to program biology to generate optimal therapeutics for the greatest impact on human health. Central to our vision is the Generate Platform, designed to be a therapeutic area and protein modality agnostic system integrating computational innovation with scalable biohardware to address therapeutic challenges beyond the reach of traditional technologies. We have built our Generate Platfo... [Read more]
News
Generate Biomedicines Begins IPO Push With Major Collaboration Deals
Generate Biomedicines is pursuing an IPO to fund its clinical trials and pipeline expansion efforts. GENB's lead asset, GB-0895, targets severe asthma and COPD, with Phase 3 enrollment expected to be ...
Generate Biomedicines, Clinical-Stage Generative Biology Company Designing AI-Engineered Protein Therapeutics, Files for Nasdaq IPO
Generate Biomedicines filed for an initial public offering on Nasdaq under the symbol GENB.
Generate Biomedicines IPO Registration Document (S-1)
Generate Biomedicines has filed to go public with an IPO on the NASDAQ
Asthma-focused AI biotech Generate Biomedicines files for a $100 million US IPO
Generate Biomedicines, a Phase 3 biotech using an AI drug discovery platform to develop severe asthma therapies, filed on Wednesday with the SEC to raise up to $100 million in an initial public offeri...